## 4 Conclusions  
Globimetulin B (**5**) isolated from the entire plant of _Globimetula dinklagei_ was the only compound that simultaneously exhibited AChE, 15-LOX and NO production inhibitory activities, as well as high binding scores with BACE1, TPK-1 and 15-LOX-2 targets. Globimetulin B can therefore represent a potential candidate for drug development against AD and other inflammation-related diseases. Additionally, other compounds such as 3-O-\(\beta\)-D  
Figure 4: Visualization of protein–ligand interactions using BIOVIA-DSV software; (**A**): protein–ligand interactions between M_iNOS and ligand_3 (\(-\)11.4 kcal/mol); (**B**): protein–ligand interactions between H_iNOS and ligand_3 (\(-\)10.9 kcal/mol); (**C**): protein–ligand interactions between CDK5 and ligand_3 (\(-\)10.4 kcal/mol) and (**D**): protein–ligand interactions between BACE1 and ligand_3 (\(-\)10.1 kcal/mol). Ligand_3: apigenin-8-C-\(\beta\)-D-glucopyranoside.  
glucopyranosyl-28-hydroxy-\(\alpha\)-amyrin (**2**), apigenin- 8-C-\(\beta\)-D-glucopyranoside (**3**), globimetulin C (**6**) and 3\(\beta\)-acetoxy-11,12-epoxytaraxerol (**9**) that were active either against AChE and/or 15-LOX and which showed effectiveness against the AChE, 15-LOX-2 and M_iNOS targets can also be valorized with respect to their therapeutic value. The current study also opens a further research direction aiming to investigate the structure-activity relationship of taraxerol derivatives against AChE. Furthermore, the docking results were in agreement with in vitro experimental data for globimetulin B and bangwausrene B against 15-LOX-2 while a disagreement was observed for 7\(\beta\),15\(\alpha\)-dihydroxy-3\(\beta\)-palmitatelup-20(29)-ene and 3\(\beta\)-acetoxy-11,12-epoxytaraxerol against AChE. This finding confirmed the importance of combining _in silico_ and _in vitro_ methods to generate the most accurate and reliable results.  
Conceptualization, E.M.N. and H.L.D.M.; Methodology, E.M.N., S.S.S. and H.L.D.M.; software, E.M.N., S.S.S. and C.I.C.; validation, E.M.N., S.S.S., Y.M.N.M., P.M. and C.I.C.; formal analysis, E.M.N., S.S.S., H.L.D.M., P.M. and C.I.C.; investigation, E.M.N., H.L.D.M. and P.M.; resources, T.J.M.; S.S.M. and L.J.M.; data curation, E.M.N., Y.M.N.M. and H.L.D.M.; writing--original draft preparation, E.M.N., S.S.S. and H.L.D.M.; writing--review and editing, E.M.N., S.S.S., H.L.D.M., P.M., C.I.C., T.J.M., S.S.M. and L.J.M.; visualization, E.M.N., H.L.D.M. and P.M.; supervision, E.M.N., P.M., T.J.M., S.S.M. and L.J.M.; project administration, E.M.N., H.L.D.M. and P.M.; funding acquisition, E.M.N., T.J.M., S.S.M. and L.J.M. All authors have read and agreed to the published version of the manuscript.  
This research was funded by the Central University of Technology operational expenses (RES. 10/22/04 awarded to E.M.N.) and the National Research Foundation (NRF), South Africa, through the Incentive Funding for Rated Researchers (awarded to L.J.M.). The APC was funded by the Central University of Technology.  
Not applicable.  
All data generated or analysed during this study are included in this published article.  
E.M.N. is very grateful to the Central University of Technology for the Track1 Postdoctoral fellowship.  
The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The authors declare that they have no competing interests.